VTRS News and Press, Viatris Inc. From 02/02/26

2026-02-02 20:49:20 ET This article is part of a series that provides an ongoing analysis of the changes made to Davis Selected Advisers’ 13F portfolio on a quarterly basis. It is based on their regulatory 13F Form filed on 02/02/2026. Please visit our Tracking Christopher ...

Viatris Expands Innovative Portfolio in Cardiovascular Diseases with the Company's First Launch of Inpefa® (Sotagliflozin) for the Treatment of Heart Failure PR Newswire Builds on Viatris' Scientific Leadership and Commercial Legacy in Cardiovascular Diseases PITTSBURGH ...

2026-01-13 16:46:02 ET Viatris Inc. (VTRS) 44th Annual J.P. Morgan Healthcare Conference January 13, 2026 12:00 PM EST... Read the full article on Seeking Alpha For further details see: Viatris Inc. (VTRS) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Viatris Appoints Lara Ramsburg as Chief People and Corporate Affairs Officer PR Newswire PITTSBURGH , Jan. 8, 2026 /PRNewswire/ --  Viatris Inc. (Nasdaq: VTRS) announced today that Lara Ramsburg has been appointed Chief People and Corporate Affairs Officer. As part of...

2026-01-07 08:00:00 ET ... Read the full article on Seeking Alpha For further details see: ADPV: Market Timing ETF With High Fees And Average Results

2026-01-02 11:02:44 ET More on markets Big three ETFs: SPY, VOO, and IVV together attract $200B in 2025 BTIG’s 2026 top picks report spotlights 21 large-cap stocks to watch Apollo sees the U.S. economy starting 2026 from a position of strength From r...

2025-12-30 08:57:41 ET Since my October article , Biogen Inc. ( BIIB ) stock has risen 18.4%, outperforming the S&P 500 [2.9% return] ( SPY ), as well as two "bellwethers" for the biotech investors, the iShares Biotechnology ETF [14%] ( IBB ) and VanEck Biotech ETF [...

2025-12-22 08:30:48 ET Now that 2025 is nearing its close and the holidays are upon us, I want to wish readers a joyous year-end holiday season. You likely have festivities to attend (and I do too), but as the year winds down I wanted to close with my annual performance review. Busi...

2025-12-22 07:48:39 ET It has been nearly three years since I last reviewed the prospects for shares of Viatris ( VTRS ) . At the start of 2023, I wondered where the cure was after a disappointing performance since the 2019 mega tie-up between the off-patented businesses of Myla...

Viatris Provides Pipeline Update on Four Regulatory Milestones PR Newswire Receives U.S. Food and Drug Administration (FDA) Approval for Generic Version of Sandostatin ® LAR Depot (Octreotide Acetate for Injectable Suspension) U.S. FDA Accepts New Drug Application for L...